Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Rigel ( (RIGL) ).
On January 12, 2026, Rigel reported strong preliminary 2025 results, with fourth-quarter total revenue expected at $69.8 million, up from $57.6 million a year earlier, and full-year revenue projected at $294.3 million versus $179.3 million in 2024, driven by 60% growth in net product sales to $232.0 million and a doubling of cash and investments to about $154.6 million. The company highlighted continued profitability, robust commercial momentum across TAVALISSE, GAVRETO and REZLIDHIA, and advancing clinical programs, including encouraging Phase 1b data for R289 in lower-risk myelodysplastic syndrome, new data and studies for olutasidenib and pralsetinib, and an FDA-approved boxed warning update for GAVRETO, while guiding to 2026 revenue of $275–$290 million and signaling confidence in sustained growth and an expanding oncology and hematology franchise.
The most recent analyst rating on (RIGL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.
Spark’s Take on RIGL Stock
According to Spark, TipRanks’ AI Analyst, RIGL is a Outperform.
Rigel Pharmaceuticals scores well due to its strong financial performance and positive earnings call, which highlight robust revenue growth and strategic advancements. The technical analysis and valuation suggest moderate momentum and potential undervaluation, while recent corporate events further bolster the company’s growth outlook.
To see Spark’s full report on RIGL stock, click here.
More about Rigel
Rigel Pharmaceuticals, Inc., based in South San Francisco, is a commercial-stage biotechnology company focused on hematologic disorders and cancer, marketing products such as TAVALISSE for chronic immune thrombocytopenia, GAVRETO for RET fusion-positive cancers, and REZLIDHIA (olutasidenib) for relapsed or refractory IDH1-mutated acute myeloid leukemia, while advancing pipeline candidates including the IRAK1/4 inhibitor R289 for lower-risk myelodysplastic syndromes.
Average Trading Volume: 602,774
Technical Sentiment Signal: Strong Buy
Current Market Cap: $807.7M
For detailed information about RIGL stock, go to TipRanks’ Stock Analysis page.